Intellia Therapeutics, Inc. (NTLA): Revenue
$67.67M
Year ended 2025-12-31
$59.51M
Trailing 12 months to 2026-06-30
+9.1%
3-year compound annual growth
+3.1%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $67.67M | +16.9% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $57.88M | +59.6% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $36.27M | -30.4% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $52.12M | +57.7% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $33.05M | -43.0% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $57.99M | +34.5% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $43.10M | +41.6% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $30.43M | +16.5% | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | $26.12M | +58.5% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $16.48M | n/a | 2019-02-27, From 2016-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $67.67M | +16.9% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $40.52M | +7.4% |
| Immucell Corp (ICCC) | 2025-12-31 | $27.64M | +4.3% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $9.22M | +0.4% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $8.65M | +5.6% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $824.50M | -1.6% |
| Neogen Corp (NEOG) | 2026-05-31 | $870.40M | -2.7% |
| Biomerica Inc (BMRA) | 2026-05-31 | $4.45M | -16.2% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $4.05M | +115.6% |
Compare NTLA, TKNO, ICCC, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗